Drug Profile


Alternative Names: SB-939

Latest Information Update: 26 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator S*BIO
  • Developer Helsinn; MEI Pharma; S*BIO; University of Texas M. D. Anderson Cancer Center
  • Class Acrylamides; Antineoplastics; Hydroxamic acids; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Myelodysplastic syndromes; Myelofibrosis

Most Recent Events

  • 23 Jun 2017 Phase-III clinical trials in Acute myeloid leukaemia (Combination therapy, Newly diagnosed) in USA (PO) (NCT03151408)
  • 12 Jun 2017 Helsinn initiates enrolment in a phase II trial for Myelodysplastic syndromes (Combination therapy) in USA (NCT03151304)
  • 05 Jun 2017 Efficacy data from a phase II trial in Acute myeloid leukaemia presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top